Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
While mu opioid receptor (MOR) agonists are especially effective as broad-spectrum pain relievers, it has been exceptionally difficult to achieve a clear separation of analgesia from many problematic side effects. Recently, many groups have sought MOR agonists that induce minimal βarrestin-mediated signaling because MOR agonist-treated βarrestin2 knockout mice were found to display enhanced antinociceptive effects with significantly less respiratory depression and tachyphylaxis. Substantial data now exists to support the premise that G protein signaling biased MOR agonists can be effective analgesic agents. We recently showed that, within a chemical series, the degree of bias correlates linearly with the magnitude of the respiratory safety index. Herein we describe the synthesis and optimization of piperidine benzimidazolone MOR agonists that together display a wide range of bias (G/βarr2). We identify structural features affecting potency and maximizing bias and show that many compounds have desirable properties, such as long half-lives and high brain penetration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Taken together, the functional data reported here and elsewhere (Kennedy et al., 2018; Schmid et al., 2017) point towards a higher in vitro activity of chlorphine and brorphine (and iodorphine), compared to fluorphine and orphine, across two signaling pathways at MOR.”
From Elucidating the harm potential of brorphine analogues as new synthetic opioids: Synthesis, in vitro, and in vivo characterization (2024) · cites this paper as Kennedy et al., 2018
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Limited pharmacological information is available in the scientific literature for orphine, fluorphine, and chlorphine (Janssen and Van der Eycken, 1968; Kennedy et al., 2018; Schmid et al., 2017); to date, there have been no studies on iodorphine.”
From Elucidating the harm potential of brorphine analogues as new synthetic opioids: Synthesis, in vitro, and in vivo characterization (2024) · cites this paper as Kennedy et al., 2018
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthes, H. W. D., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., Befort, K., Dierich, A., Le Meur, M., Dollé, P., et al. (1996) · Nature · doi:10.1038/383819a0 · Cited by 1,722
Functional Selectivity and Classical Concepts of Quantitative Pharmacology
Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104463 · Cited by 1,116
Enhanced Morphine Analgesia in Mice Lacking β-Arrestin 2
Bohn, L. M., Lefkowitz, R. J., Gainetdinov, R. R., Peppel, K., Caron, M. G., & Lin, F.-T. (1999) · Science · doi:10.1126/science.286.5449.2495 · Cited by 1,077
Self-citationOperational models of pharmacological agonism
Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society of London. Series B. Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 951
Structure-based discovery of opioid analgesics with reduced side effects
Manglik, A., Lin, H., Aryal, D. K., McCorvy, J. D., Dengler, D., Corder, G., Levit, A., Kling, R. C., Bernat, V., Hübner, H., et al. (2016) · Nature · doi:10.1038/nature19112 · Cited by 944
μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence
Bohn, L. M., Gainetdinov, R. R., Lin, F.-T., Lefkowitz, R. J., & Caron, M. G. (2000) · Nature · doi:10.1038/35047086 · Cited by 927
Self-citationOverdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016.
Seth, P., Scholl, L., Rudd, R. A., & Bacon, S. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6712a1 · Cited by 821
DeWire, S. M., Yamashita, D. S., Rominger, D. H., Liu, G., Cowan, C. L., Graczyk, T. M., Chen, X.-T., Pitis, P. M., Gotchev, D., Yuan, C., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201616 · Cited by 647
Morphine Side Effects in β-Arrestin 2 Knockout Mice
Raehal, K. M., Walker, J. K. L., & Bohn, L. M. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087254 · Cited by 626
Self-citationBias factor and therapeutic window correlate to predict safer opioid analgesics
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567
Self-citation
Cited by
Faouzi, A., Varga, B. R., & Majumdar, S. (2020) · Molecules · doi:10.3390/molecules25184257 · Cited by 157
“3 G-protein 153 (GTPγS) 91 >10,000 (PathHunter) 12 NA [34]”
BackgroundInfluentialDARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles
Ujváry, I., Christie, R., Evans-Brown, M., Gallegos, A., Jorge, R., de Morais, J., & Sedefov, R. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00037 · Cited by 141
The Opioid Crisis and the Future of Addiction and Pain Therapeutics
Coussens, N. P., Sittampalam, G. S., Jonson, S. G., Hall, M. D., Gorby, H. E., Tamiz, A. P., McManus, O. B., Felder, C. C., & Rasmussen, K. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.259408 · Cited by 106
“Studies were presented of a m-opioid agonist series (Schmid et al., 2017; Kennedy et al., 2018) with favorable bias factors for guano-”
MethodBiased Agonism: Lessons from Studies of Opioid Receptor Agonists
Kelly, E., Conibear, A. E., & Henderson, G. (2022) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052120-091058 · Cited by 107
Toward Directing Opioid Receptor Signaling to Refine Opioid Therapeutics
Grim, T. W., Acevedo-Canabal, A., & Bohn, L. M. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.10.020 · Cited by 85
“4- to 100-fold preference as measured by either GTPγS binding or cAMP accumulation versus either βarrestin2 recruitment PathHunter® enzymatic complementation or recruitment of GFP-conjugated βarrestin2 (59, 60).”
BackgroundSelf-citation
Metadata
- Authors
- Kennedy, N. M., Schmid, C. L., Ross, N. C., Lovell, K. M., Yue, Z., Chen, Y. T., Cameron, M. D., Bohn, L. M., & Bannister, T. D.
- Affiliations
- Scripps Research Institute (US)
- Corresponding author
- Bohn, Laura M.
- Bannister, Thomas D.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-09-10
- Volume
- 61
- Issue
- 19
- Pages
- 8895-8907
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- PMC
- PMC6386185
- OpenAlex
- W2891113839
- Cited by
- 71
- References
- 32
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 8 · 2023: 3 · 2022: 11 · 2021: 14 · 2020: 14 · 2019: 6
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (R01DA038694, R01DA033073)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- mu-opioid receptor agonists, β-arrestin2, benzimidazolone derivatives, piperidine derivatives, analgesia, respiratory depression, tachyphylaxis, structure-activity optimization, brain penetration, opioid side effects
- MeSH terms
- beta-Arrestins, Analgesics, Opioid, Animals, Blood-Brain Barrier, Humans, Male, Mice, Inbred C57BL, Microsomes, Liver, Protein Conformation, Structure-Activity Relationship, Receptors, Opioid, mu, GTP-Binding Proteins, Mice, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias. https://app.cochat.ai/papers/10.1021/acs.jmedchem.8b01136
- The paper
- Kennedy, N. M., Schmid, C. L., Ross, N. C., Lovell, K. M., Yue, Z., Chen, Y. T., Cameron, M. D., Bohn, L. M., & Bannister, T. D. (2018). Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.8b01136
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.